# Malaria Therapeutic Efficacy Study, Rwanda

> **NCT04767217** · PHASE4 · COMPLETED · sponsor: **Jhpiego** · enrollment: 528 (actual)

## Conditions studied

- Uncomplicated Malaria

## Interventions

- **DRUG:** artemether-lumefantrine (ALN)
- **DRUG:** dihydroartemisinin-piperaquine (DHA-PPQ)

## Key facts

- **NCT ID:** NCT04767217
- **Lead sponsor:** Jhpiego
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-14
- **Primary completion:** 2023-12-08
- **Final completion:** 2024-01-31
- **Target enrollment:** 528 (ACTUAL)
- **Last updated:** 2024-02-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04767217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04767217, "Malaria Therapeutic Efficacy Study, Rwanda". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04767217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*